Program
secukinumab
Also written as “Secukinumab”, “AIN457” and “Secukinumab 300 mg”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylitis, Ankylosing · Arthritis, Rheumatoid · Hidradenitis Suppurativa, led by 3 companies.
Drug pageSecukinumab: every studyAll 177 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 1254 open or running | phase 4since Jul 12, 2015 | Dec 21, 2007 | Feb 8, 2028phase 4 · NCT05622708 |
| Taizhou Mabtech Pharmaceuticalits history only | 20 open or running | phase 1since Jan 29, 2023 | Jan 29, 2023 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since Oct 13, 2020 | Oct 13, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2020First study: phase 1 study in HealthyFirst studyNCT04589026 · 12 enrolled · Belgium
TargetBeta
“A recombinant human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), ”NCIt, by rule
“Interleukin 17A inhibitor”ChEMBL 37, by rule
Other programs on IL17A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ixekizumabrule | Eli Lilly | phase 4 | 38 |
| vunakizumabrule | Jiangsu HengRui Medicine | phase 4 | 17 |
| bimekizumabrule | UCB | phase 3 | 43 |
| sonelokimabrule | moonlake-immunotherapeutics-ag | phase 3 | 12 |
| simepdekinra | Eli Lilly | phase 2 | 7 |
| tibulizumabrule | Eli Lilly | phase 2 | 5 |
| SCT650Crule | Sinocelltech Group | phase 2 | 3 |
| UA026rule | usynova-pharmaceuticals-ltd | phase 1 | 1 |
Studies
The one study Johnson & Johnson leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04589026Healthy · Belgium | 1 | Completed | May 6, 2021 | 12 |
How it is read
Names in the registry
- “Secukinumab”, 47 entries
- “AIN457”, 38 entries
- “secukinumab”, 7 entries
- “Secukinumab 300 mg”, 6 entries
- “Secukinumab (AIN457)”, 6 entries
Conditions, from the studies’ own filings
- Psoriasis, 39 studies
- Arthritis, Psoriatic, 16 studies
- Spondylitis, Ankylosing, 13 studies
- Arthritis, Rheumatoid, 7 studies
- Hidradenitis Suppurativa, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.